Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma

Conclusion Even with baseline −Cyt, ∼25% of patients develop PC following multimodality therapy. Patients who do not develop PC have an excellent OS rate. Further research is warranted to detect PC at baseline by the use of biomarkers.

Source: Journal of Surgical Oncology - December 4, 2017 Category: Cancer & Oncology Authors: Dilsa Mizrak Kaya, Graciela M. Nogueras ‐González, Kazuto Harada, Fatemeh G. Amlashi, Sinchita Roy‐Chowdhuri, Jeannelyn S. Estrella, Prajnan Das, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Aurelio Matamoros, Irene Thomas, Quan Lin, Brian D. Bad Tags: RESEARCH ARTICLE Source Type: research